Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 250

Sort by

Sort Order Select

Journal Articles

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Blood (2025) 145 (14): 1526–1535.

https://doi.org/10.1182/blood.2024026401

Published: 2025

Includes: Supplemental data

Journal Articles

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Blood blood.2024027689.

https://doi.org/10.1182/blood.2024027689

Published: 2025

Includes: Supplemental data

Journal Articles

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

De Zhou, Xianbo Huang, Lixia Zhu, Xuelian Hu, Xiudi Yang, Mixue Xie, Xin Huang, Fang Yu, Juying Wei, Liya Ma, Jingjing Zhu, Shuqi Zhao, Wanzhuo Xie, Hongyan Tong, Jie Jin, Xiujin Ye

Blood blood.2024026139.

https://doi.org/10.1182/blood.2024026139

Published: 2025

Includes: Supplemental data

Journal Articles

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Huafeng Wang, Xiaolong Zheng, Wenjuan Yu, De Zhou, Chunmei Yang, Xinping Zhou, Liping Mao, Haitao Meng, Liangshun You, Min Yang, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2024) 144 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2024-197872

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao

Blood (2024) 144 (Supplement 1): 477.

https://doi.org/10.1182/blood-2024-205300

Published: 2024

Journal Articles

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

Blood (2024) 144 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2024-212216

Published: 2024

Journal Articles

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Lihong Shou, Qingchi Liu, Feng Zhang, Cuicui WU, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2024) 144 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2024-210330

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Metabolic Signature of Oxidative Phosphorylation Deficiency with Activated Nucleotide Biosynthesis in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Yinghui Zhu, Bowen Wu, Tianyi Chen, Miaomiao Liu, Shangyu Hou, Xuemei Wang, Yiyi Yao, Tao Zeng, Jinyan Huang, Jie Jin, Huafeng Wang

Blood (2024) 144 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2024-205224

Published: 2024

Journal Articles

Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia

Yinjun Lou, Jie Jin, Hongyan Tong, Shanshan Suo, Huafeng Wang, Liping Mao, Haitao Meng, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 1526.

https://doi.org/10.1182/blood-2024-209944

Published: 2024

Journal Articles

Integrating Spatial Transcriptome, Single-Cell Sequencing and Histopathology Reveals Bone Marrow Spatial Heterogenous in AML Patients

Xiangjie Lin, Huafeng Wang, Jie Jin

Blood (2024) 144 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2024-205328

Published: 2024

Journal Articles

The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Yanan Zhu, Yunfei Lv, Xingnong Ye, Juying Wei, Lixia Sheng, Ying Lin, Xiang Zhang, Xuewu Zhang, Hongyan Tong, Jie Jin, Wen-Juan Yu

Blood (2024) 144 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2024-198711

Published: 2024

Journal Articles

Real-World Outcomes in Grade 3B Follicular Lymphoma and Composite Follicular Lymphoma with Diffuse Large B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study in China

Yufei Lv, Xiang Zhang, Yanan Zhu, Juying Wei, Xuewu Zhang, Xingnong Ye, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2024-202204

Published: 2024

Journal Articles

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Blood (2024) 144 (Supplement 1): 6602.

https://doi.org/10.1182/blood-2024-208258

Published: 2024

Journal Articles

Effects and Molecular Mechanism of Inhibiting p53 Signaling Pathway By NSUN6 on the Resistance to BCL-2 Inhibitor for Diffuse Large B-Cell Lymphoma

Yuanfei Shi, Yanchun Zhao, Yi Xu, Jianai Sun, Xiaolong Zheng, De Zhou, Jie Jin, Hongyan Tong, Wanzhuo Xie

Blood (2024) 144 (Supplement 1): 6238.

https://doi.org/10.1182/blood-2024-202205

Published: 2024

Journal Articles

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

Xuewu Zhang, Haitao Meng, Gaixiang Xu, Min Yang, Wanzhuo Xie, Juying Wei, Liya Ma, Xingnong Ye, Liping Mao, Wenyuan Mai, Chunmei Yang, Yanling Ren, Hongyan Tong, Yanan Zhu, Xiang Zhang, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6772.

https://doi.org/10.1182/blood-2024-203639

Published: 2024

Journal Articles

Combined Targeting of SYK and BCL-2 in Acute Myeloid Leukaemia and Mechanism Study

Lili Jin, Xia Jiang, Youhong Li, Lei Jiang, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 5738.

https://doi.org/10.1182/blood-2024-204796

Published: 2024

Journal Articles

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Yiyi Yao, Yile Zhou, Nanfang Zhuo, Wanzhuo Xie, Haitao Meng, Yinjun Lou, Liping Mao, Hongyan Tong, Jiejing Qian, Min Yang, Wenjuan Yu, De Zhou, Jian Huang, Jie Jin, Huafeng Wang

Blood (2024) 144 (Supplement 1): 7485.

https://doi.org/10.1182/blood-2024-204411

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

Screening and Validation of Natural Product with Anti ETP-ALL Activity Using a Novel ETP-ALL Cell Line

Fenglin Li, Haihui Zhuang, Renzhi Pei, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 5847.

https://doi.org/10.1182/blood-2024-204632

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Metabolic Signature of Oxidative Phosphorylation Deficiency with Activated Nucleotide Biosynthesis in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia

Integrating Spatial Transcriptome, Single-Cell Sequencing and Histopathology Reveals Bone Marrow Spatial Heterogenous in AML Patients

The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Real-World Outcomes in Grade 3B Follicular Lymphoma and Composite Follicular Lymphoma with Diffuse Large B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study in China

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Effects and Molecular Mechanism of Inhibiting p53 Signaling Pathway By NSUN6 on the Resistance to BCL-2 Inhibitor for Diffuse Large B-Cell Lymphoma

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

Combined Targeting of SYK and BCL-2 in Acute Myeloid Leukaemia and Mechanism Study

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Screening and Validation of Natural Product with Anti ETP-ALL Activity Using a Novel ETP-ALL Cell Line

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only